Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai “Strongly Opposes” Medicare Coverage Proposal for Aduhelm, Calls for Revisit
January 14, 2022
- Kitasato Institute, Sumitomo Dainippon’s KSP-1007 Enters US PI Study for Carbapenem-Resistant Bacterial Infections
January 14, 2022
- Keytruda, Opdivo Neck and Neck in 2021; 6 Drugs Cross 100 Billion Yen Mark: Encise
January 13, 2022
- Sawai to Launch E Keppra Granule Tablets on Feb. 1
January 13, 2022
- Daiichi Sankyo to Shutter Plexxikon to Maximize Investment in ADCs
January 13, 2022
- Ex-CMIC Exec Philippe Auvaro Joins Medical Data Vision
January 12, 2022
- Takeda Pushes Back Assumed Biosimilar Entry in US by 3-5 Years
January 12, 2022
- Takeda to Buy Adaptate to Bolster I/O Pipeline
January 12, 2022
- Japan Ethical Drug Sales Zoom 8.9% in November: Crecon
January 12, 2022
- Gilead Names US VP Kennet Brysting as New Japan Chief
January 12, 2022
- Mitsubishi Chemical Holdings Plans Organizational Rejig in April, Ueno to Helm Pharma Unit
January 11, 2022
- Kissei/Maruishi’s Pruritus Drug Hits Mark in Japan PIII Study
January 11, 2022
- Rexulti Expands Label into Pediatric Schizophrenia in US
January 11, 2022
- Sosei Inks GPCR Strategic Collaboration with Google’s Verily
January 11, 2022
- Takecab Tops Japan Sales Ranking in December: Encise
January 11, 2022
- Riken Genesis’s AmoyDx Now Available as CDx for Takeda’s ALK Inhibitor Alunbrig
January 7, 2022
- Eisai Awards Exclusive Rights for Splicing Modulator H3B-8800 to Roivant
January 7, 2022
- Opdivo Gets Adjuvant Nod for Esophageal Cancer in Taiwan: Ono
January 6, 2022
- Shionogi’s COVID-19 Pill Submission Delaying into 2022 as Recruitment Hits Snag
January 6, 2022
- Detailing Activities Rise in All Promotion Channels MOM, YOY in November: Intage
January 6, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…